ion 682884
Nucleic acidexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Jun 1, 2021 (NCT04843020)
Timeline
Indications
Mechanism of action
- TransthyretinANTISENSE INHIBITOR
TTR antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06194825 | Phase 3 | Dec 1, 2023 | AstraZeneca |
| NCT05667493 | Phase 3 | Nov 30, 2022 | AstraZeneca, Ionis Pharmaceuticals, Inc. |
| NCT05071300 | Phase 3 | Oct 31, 2021 | Ionis Pharmaceuticals, Inc. |
| NCT04843020 | Phase 2 | Jun 1, 2021 | Harvard University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 1 | 1 | 2022 |
| Ionis Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1